Home / Market News / $BIIB
benzinga Corporate Catalyst Impact 65/100 ● positive

Biogen Announces Data From Phase 2 Part Of Its Current AMETHYST Phase 2/3 Trial Of Litifilimab In Participants With Cutaneous Lupus Erythematosus Demonstrates 27.2% Of Patients At Week 52 Achieve Clinical Endpoint Of Clear Or Utmost Clear Skin; Litifilimab Seen To Be Generally Well Tolerated

Oct 2, 2026, 3:26 PM UTC · Primary ticker $BIIB

Biogen announced positive 52-week results from the Phase 2 part of its AMETHYST trial for litifilimab in cutaneous lupus erythematosus (CLE). The data indicates continued clinical improvements and rapid onset of treatment effect, supporting the drug's potential in this indication.

Biogen announced 52-week results from the Phase 2 part of its AMETHYST trial for litifilimab in cutaneous lupus erythematosus (CLE). The data showed continued clinical improvements and a rapid onset of treatment effect, with 27.2% of patients achieving clear or utmost clear skin at Week 52. This positive update extends the known efficacy and safety profile of litifilimab, which is a key pipeline asset for Biogen. For traders, this represents a positive long-term development for BIIB, potentially de-risking the drug's path to market and strengthening its future revenue streams, though the immediate market reaction might be moderate as this is Phase 2 data.

$BIIB positive Positive clinical trial results for key pipeline asset
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.